Symptom and Quality of Life Improvement in LUX-Lung 8, an Open-Label Phase III Study of Second-Line Afatinib Versus Erlotinib in Patients With Advanced Squamous Cell Carcinoma of the Lung After First-Line Platinum-Based Chemotherapy.
View/ Open
Date
2018-01Author
Felip, E
Hirsh, V
Popat, S
Cobo, M
Fülöp, A
Dayen, C
Trigo, JM
Gregg, R
Waller, CF
Soria, J-C
Goss, GD
Gordon, J
Wang, B
Palmer, M
Ehrnrooth, E
Gadgeel, SM
Type
Journal Article
Metadata
Show full item recordAbstract
Introduction In the phase III LUX-Lung 8 trial, afatinib significantly improved progression-free survival (PFS) and overall survival (OS) versus erlotinib in patients with squamous cell carcinoma (SCC) of the lung progressing during or after platinum-based chemotherapy. Patient-reported outcomes (PROs) and health-related quality of life (QoL) in these patients are presented.Patients and methods Patients (n = 795) were randomized 1:1 to oral afatinib (40 mg/d) or erlotinib (150 mg/d). PROs were collected (baseline, every 28 days until progression, 28 days after discontinuation) using the European Organization for Research and Treatment of Cancer QoL questionnaire and lung cancer-specific module. The percentage of patients improved during therapy, time to deterioration (TTD), and changes over time were analyzed for prespecified lung cancer-related symptoms and global health status (GHS)/QoL.Results Questionnaire compliance was 77.3% to 99.0% and 68.7% to 99.0% with afatinib and erlotinib, respectively. Significantly more patients who received afatinib versus erlotinib experienced improved scores for GHS/QoL (36% vs. 28%; P = .041) and cough (43% vs. 35%; P = .029). Afatinib significantly delayed TTD in dyspnea (P = .008) versus erlotinib, but not cough (P = .256) or pain (P = .869). Changes in mean scores favored afatinib for cough (P = .0022), dyspnea (P = .0007), pain (P = .0224), GHS/QoL (P = .0320), and all functional scales. Differences in adverse events between afatinib and erlotinib, specifically diarrhea, did not affect GHS/QoL.Conclusion In patients with SCC of the lung, second-line afatinib was associated with improved prespecified disease-related symptoms and GHS/QoL versus erlotinib, complementing PFS and OS benefits with afatinib.
Collections
Subject
Humans
Carcinoma, Squamous Cell
Lung Neoplasms
Platinum Compounds
Antineoplastic Combined Chemotherapy Protocols
Neoplasm Staging
Survival Analysis
Quality of Life
Middle Aged
Female
Male
Erlotinib Hydrochloride
Patient Reported Outcome Measures
Afatinib
Research team
Thoracic Oncology
Language
eng
Date accepted
2017-06-13
License start date
2018-01
Citation
Clinical lung cancer, 2018, 19 (1), pp. 74 - 83.e11